{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026608","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.455302+00:00","generated_at":"2026-06-22T01:00:24.514295+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA maintains clinical hold on DM199 stroke trial; company to conduct additional IV stability study","bullets":["FDA requires additional in-use in vitro stability study of IV administration of DM199 to resolve clinical hold on ReMEDy2 trial.","Company to request Type A meeting with FDA in coming weeks for guidance on lifting hold.","Cash and investments $36.1M as of Sep 30, 2022, down from $45.1M at Dec 31, 2021; runway into Q4 2024.","R&D expense Q3 2022 $1.6M (down from $2.3M Q3 2021); G&A $1.5M (up from $1.1M).","Net cash used in operating activities $8.7M for 9mo 2022, compared to $9.4M in 9mo 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026608","json":"https://secwatch.observer/filing/0001437749-22-026608.json","markdown":"https://secwatch.observer/filing/0001437749-22-026608.md","text":"https://secwatch.observer/filing/0001437749-22-026608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922026608/0001437749-22-026608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922026608/dmtp20221108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:00:24.514295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6979eff73f38d139e56b58504789fbbc0972ab6","claim":"DiaMedica Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922026608/0001437749-22-026608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}